| Anti-SEMA4D Monoclonal Antibody VX15/2503 With Nivolumab or Ipilimumab in Treating Patients With Stage III or IV Melanoma (NCT03425461) | Jonsson Comprehensive Cancer Center | 2018-06-14 |
| Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma (NCT02965716) | National Cancer Institute (NCI) | 2018-06-05 |
| Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery (NCT03326258) | National Cancer Institute (NCI) | 2018-04-20 |
| Dendritic Cell Therapy With Pembrolizumab for Metastatic or Unresectable Melanoma (NCT03325101) | Mayo Clinic | 2017-11-15 |
| Pembrolizumab and Ibrutinib in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery (NCT03021460) | Mayo Clinic | 2017-01-31 |
| Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma (NCT02910700) | M.D. Anderson Cancer Center | 2016-12-09 |
| A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma (NCT02339571) | National Cancer Institute (NCI) | 2015-11-23 |
| Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas (NCT02304458) | National Cancer Institute (NCI) | 2015-03-30 |
| Genetically Modified Therapeutic Autologous Lymphocytes Followed by Aldesleukin in Treating Patients With Stage III or Metastatic Melanoma (NCT01740557) | M.D. Anderson Cancer Center | 2015-01-28 |
| Genetically Modified T-Cells Followed by Aldesleukin in Treating Patients With Stage III-IV Melanoma (NCT01955460) | M.D. Anderson Cancer Center | 2014-10-15 |
| Testing Two Different Treatment Schedules of Dabrafenib and Trametinib for Skin Cancer Which Has Spread (NCT02196181) | National Cancer Institute (NCI) | 2014-09-19 |
| Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery (NCT02097225) | National Cancer Institute (NCI) | 2014-05-29 |
| A Vaccine (CDX-1401) With or Without a Biologic Drug (CDX-301) for the Treatment of Patients With Stage IIB-IV Melanoma (NCT02129075) | National Cancer Institute (NCI) | 2014-04-09 |
| Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by Surgery (NCT01940809) | National Cancer Institute (NCI) | 2013-08-28 |
| Tumor-Infiltrating Lymphocytes After Combination Chemotherapy in Treating Patients With Metastatic Melanoma (NCT01807182) | Fred Hutchinson Cancer Center | 2013-08-20 |
| Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction (NCT01638533) | National Cancer Institute (NCI) | 2012-08-03 |
| Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer (NCT01480154) | National Cancer Institute (NCI) | 2011-11-23 |
| Riluzole and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors or Melanoma (NCT01303341) | National Cancer Institute (NCI) | 2011-02-18 |
| Aldesleukin With or Without Ziv-Aflibercept in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery (NCT01258855) | National Cancer Institute (NCI) | 2011-01-18 |
| Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery (NCT01134614) | National Cancer Institute (NCI) | 2010-12-28 |